Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Moodys
Citi
Covington
Medtronic
Accenture
QuintilesIMS
Fuji
Colorcon

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NONOXYNOL-9

« Back to Dashboard

Clinical Trials for Nonoxynol-9

Trial ID Title Status Sponsor Phase Summary
NCT00000926 A Study of Nonoxynol-9 (N-9) and HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV. Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases.
NCT00000929 A Study of the Effects of Advantage 24 on the Rectum Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm). Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions.
NCT00016536 Effects of BufferGel and PRO 2000/5 Gel in Men Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 The purpose of this study is to find out if there are any bad effects when BufferGel or PRO 2000/5 Gel are applied to the penis of HIV-infected men. Microbicides are products to be used by women for placing into the vagina to prevent passing HIV from 1 person to another during sex. Studies have shown 2 investigational microbicides, BufferGel and PRO 2000/5 Gel, to be safe and acceptable for women and HIV-negative men. It is important to see if the side effects of these products are the same in men as those in women and to see if there is any difference in the side effects between circumcised and uncircumcised men.
NCT00262106 Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Completed Department for International Development, United Kingdom Phase 3 The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
NCT00262106 Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Completed Medical Research Council Phase 3 The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
NCT00262106 Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Completed Endo Pharmaceuticals Phase 3 The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
NCT00692952 Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial Completed Chang Jiang Bio-pharmaceutical Co., Ltd. Phase 2 A multicentric clinical trial in three Chinese Maternal and Child Hospitals was conducted to evaluate the efficacy, safety and acceptability of newly-developed vaginal contraceptive gel, the optimized benzalkonium chloride (BZK) gel containing 18mg BZK, with comparison to a currently marketed (in China)contraceptive gel LELEMI® containing 50mg Nonoxynol-9 (N-9).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nonoxynol-9

Condition Name

Condition Name for Nonoxynol-9
Intervention Trials
HIV Infections 4
Rectal Microbicides 1
Chlamydial Infections 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nonoxynol-9
Intervention Trials
HIV Infections 4
Infection 2
Communicable Diseases 2
Acquired Immunodeficiency Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nonoxynol-9

Trials by Country

Trials by Country for Nonoxynol-9
Location Trials
United States 27
Russian Federation 3
South Africa 1
Zambia 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nonoxynol-9
Location Trials
Washington 3
Alabama 2
North Carolina 2
Pennsylvania 2
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nonoxynol-9

Clinical Trial Phase

Clinical Trial Phase for Nonoxynol-9
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nonoxynol-9
Clinical Trial Phase Trials
Completed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nonoxynol-9

Sponsor Name

Sponsor Name for Nonoxynol-9
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 4
CONRAD 2
Endo Pharmaceuticals 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nonoxynol-9
Sponsor Trials
Other 10
NIH 4
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Dow
Deloitte
Express Scripts
Merck
Julphar
Healthtrust
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.